R2CHADS2 Score: An Effective Risk Stratification Tool for Contrast-Induced Nephropathy and Cardiovascular Outcomes in STEMI Patients Undergoing PCI

Sahin Y. B., KIZILTUNÇ E., CANDEMİR M.

ANGIOLOGY, 2025 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1177/00033197251383333
  • Dergi Adı: ANGIOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, CINAHL, EMBASE, Food Science & Technology Abstracts
  • Gazi Üniversitesi Adresli: Evet

Özet

Contrast-induced nephropathy (CIN) is a serious complication following percutaneous coronary intervention (PCI). The Renal dysfunction, Congestive heart failure, Hypertension, Age >= 75 years, Diabetes mellitus and prior Stroke R2CHADS2 score, originally developed for thromboembolic risk assessment, has recently been proposed as a predictor of CIN and major adverse cardiovascular events (MACE). The present study aimed to evaluate the predictive value of the R2CHADS2 score for CIN and long-term MACE in STEMI patients undergoing primary PCI (pPCI). A total of 1204 STEMI patients were included in this retrospective study. Patients were categorized into 3 risk groups based on their R2CHADS2 scores. CIN incidence was significantly higher in the high-risk group (37.1%) compared with the moderate (13.6%) and low-risk groups (5.5%; P < .001). Hemodialysis was required in 14.3% of high-risk patients (P < .001). MACE occurred in 49.3% of the high-risk group, 22.1% of the moderate-risk group, and 12.9% of the low-risk group (P < .001). These findings suggest that the R2CHADS2 score can predict CIN and adverse cardiovascular outcomes in STEMI patients undergoing pPCI.